BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 34713897)

  • 1. Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease.
    Ravindran S; Munusamy S
    J Cell Physiol; 2022 Feb; 237(2):1182-1205. PubMed ID: 34713897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Proximal Tubular Reabsorption Modulate Microvascular Regulation via the TGF System.
    Poursharif S; Hamza S; Braam B
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interplay of adenosine monophosphate-activated protein kinase/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework.
    Packer M
    Diabetes Obes Metab; 2020 May; 22(5):734-742. PubMed ID: 31916329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tubular hypothesis of nephron filtration and diabetic kidney disease.
    Vallon V; Thomson SC
    Nat Rev Nephrol; 2020 Jun; 16(6):317-336. PubMed ID: 32152499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
    Thomson SC; Vallon V
    Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition.
    Tsimihodimos V; Filippatos TD; Filippas-Ntekouan S; Elisaf M
    Curr Vasc Pharmacol; 2017; 15(2):96-102. PubMed ID: 27748201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
    Bailey CJ; Day C; Bellary S
    Curr Diab Rep; 2022 Jan; 22(1):39-52. PubMed ID: 35113333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Sodium-glucose co-transporter 2 inhibitors: mechanisms of renal action. Implications for diabetes and heart failure].
    Gronda E; Iacoviello M; Caldarola P; Benvenuto M; Cassaniti L; Palazzuoli A; Municinò A; Napoli C; Gabrielli D
    G Ital Cardiol (Rome); 2021 Apr; 22(4):284-291. PubMed ID: 33783448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renoprotective Effects of SGLT2 Inhibitors.
    Vallon V
    Heart Fail Clin; 2022 Oct; 18(4):539-549. PubMed ID: 36216484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors.
    Kale A; Sharma A; Anders HJ; Gaikwad AB
    Curr Diabetes Rev; 2023; 19(8):e160822207546. PubMed ID: 35975848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics.
    Packer M
    Am J Kidney Dis; 2021 Feb; 77(2):280-286. PubMed ID: 32711072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
    Škrtić M; Cherney DZ
    Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):96-103. PubMed ID: 25470017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockout of Na
    Song P; Huang W; Onishi A; Patel R; Kim YC; van Ginkel C; Fu Y; Freeman B; Koepsell H; Thomson S; Liu R; Vallon V
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F207-F217. PubMed ID: 31091127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications.
    Castañeda AM; Dutra-Rufato A; Juarez MJ; Grosembacher L; Gonzalez-Torres H; Musso CG
    Int Urol Nephrol; 2021 Feb; 53(2):291-299. PubMed ID: 32767250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
    Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
    Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
    Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
    Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics.
    Kim NH; Kim NH
    Diabetes Metab J; 2022 Jul; 46(4):543-551. PubMed ID: 35929172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.